Hong Kong stock market anomaly | Tianchen Bio-B (01779.HK) surged more than 7% recently. The clinical trial application for peanut allergy indication LP-003 has been approved by the US FDA.

According to the Zhicheng Finance and Economics APP, Tianchen Biology-B (01779.HK) rose more than 7%, as of the time of the report, it had increased by 7.77% to HK$89.45, with a trading volume of HK$3.1726 million.